Analysts' Actions -- Chipotle, Nvidia, Qualcomm, Teva and More

Here are Friday's top research calls, including downgrades for Chipotle, Nvidia, Qualcomm and Teva Pharmaceuticals.
By TheStreet Staff ,

RATINGS CHANGES

AAR Corp. (AIR) - Get Report was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: AIR.

Chipotle Mexican Grill (CMG) - Get Report was downgraded to equal-weight from overweight at Morgan Stanley. $405 price target. The company is still struggling to win back customers, Morgan Stanley said. 

Equinix (EQIX) - Get Report was downgraded to hold from buy at Jefferies. The valuation is not as attractive, based on a $400 price target, Jefferies said. 

IHS Markit (INFO) - Get Report was upgraded to buy from hold at Deutsche Bank. $42 price target. Organic revenue growth can accelerate and drive solid earnings growth, Deutsche said. 

Lincoln Financial (LNC) - Get Report was downgraded to neutral at Goldman Sachs. $46 price target. The company lacks near-term catalysts, Goldman said. 

Nvidia (NVDA) - Get Report was downgraded to underperform at Wells Fargo. The company is facing increased competition from AMD and Intel, Wells Fargo said. 

PG&E (PCG) - Get Report was upgraded to outperform at RBC Capital. The valuation is more attractive, based on a $71 price target, RBC said. 

Qualcomm (QCOM) - Get Report was downgraded to underperform from market perform at BMO Capital. $50 price target. The company has multiple potential negative catalysts, BMO said. 

Ritchie Bros. (RBA) - Get Report was downgraded to hold at Jefferies. $35 price target. The valuation is less attractive, with shares up 45% year-to-date, Jefferies said. 

Select Comfort (SCSS) was upgraded to neutral from underperform at Bank of America/Merrill Lynch. $25 price target. The company will likely achieve near-term guidance, analysts said. 

SunTrust (STI) - Get Report was downgraded to underperform from neutral at Robert Baird. The valuation is less attractive, based on a $41 price target, Robert Baird said. 

Teva Pharmaceuticals (TEVA) - Get Report was downgraded to neutral from buy at Goldman Sachs. The valuation is less attractive, based on a $60 price target, Goldman said. 

Torchmark (TMK) was upgraded to neutral from sell at Goldman Sachs. $60 price target. The company has an attractive defensive profile, Goldman said. 

TSR Inc. (TSRI) - Get Report was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: TSRI.

This article was written by a staff member of TheStreet.

Loading ...